Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171)
- PMID: 18260185
- DOI: 10.1093/annonc/mdm577
Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171)
Comment on
-
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.Ann Oncol. 2007 Jul;18(7):1165-71. doi: 10.1093/annonc/mdm119. Epub 2007 Apr 17. Ann Oncol. 2007. PMID: 17442659 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical